# NCT04179162 (NCT04179162)

> Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04179162
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Memorial Sloan Kettering Cancer Center
- Conditions: Non-Muscle Invasive Bladder Cancer (NMIBC)
- Interventions: Bacillus Calmette-Guérin (BCG); Gemcitabine
- Enrollment: 54
- Primary outcome: evaluate the MTD (Phase I)
- Primary outcome: proportion of patients who are disease free

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Bluesky threads: 2
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04179162